Compare XRTX & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRTX | POAS |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Canada | Singapore |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.6M |
| IPO Year | 2018 | 2024 |
| Metric | XRTX | POAS |
|---|---|---|
| Price | $2.19 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.3K | ★ 236.3K |
| Earning Date | 05-15-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.17 |
| 52 Week High | $3.60 | $7.40 |
| Indicator | XRTX | POAS |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 33.11 |
| Support Level | $2.00 | $0.19 |
| Resistance Level | $2.24 | $0.39 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 81.25 | 24.90 |
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.